Abstract 4361884: Improvement in Echocardiographic Measures of Diastolic Function Reflects Improved Exercise Performance in Obstructive Hypertrophic Cardiomyopathy: Insights From the SEQUOIA-HCM Trial

H Henri Lu (Lausanne University Hospital, Lausanne, Switzerland) N Nicole Bart (ST VINCENTS HOSPITAL, Sydney, New South Wales, Australia) B Brian Claggett (Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston) T Theodore Abraham (Department of Cardiology, University of, California, San Francisco, San Francisco) C Caroline Coats (University og Glasgow, Glasgow, United Kingdom) M Matthew Lee G Gregory Lewis (Massachusetts General Hospital, Boston, Massachusetts, United States) M Martin maron (Lahey Hospital, Burlington, Massachusetts, United States) A Ahmad Masri (Oregon Health and Science University, Portland) I Iacopo Olivotto (Department of Cardiology, Meyer Children’s Hospital, IRCCS, Florence, Italy) D Daniel Jacoby (Cytokinetics Inc., South San Francisco, California, United States) S Stephen Heitner (Cytokinetics Inc., South San Francisco, California, United States) S Stuart Kupfer (Cytokinetics, South San Francisco, CA) F Fady Malik (Cytokinetics Inc., South San Francisco, California, United States) A Amy Wohltman (Cytokinetics, South San Francisco, CA) S Scott Solomon (Brigham and Women's Hospital, Boston, Massachusetts, United States) S Sheila Hegde (The University of Texas Southwestern Medical Center, Dallas, Texas, United States)

Abstract

Background: A hallmark feature of obstructive hypertrophic cardiomyopathy (oHCM) is impaired exercise capacity, which impacts quality of life and is a determinant of clinical outcomes. Understanding the mechanisms of exercise intolerance in oHCM remains essential to optimizing patient care. Research Question: This study addresses the relationships between changes in echocardiographic parameters and cardiopulmonary exercise testing (CPET) metrics in patients with oHCM from the SEQUOIA-HCM trial (NCT05186818). Methods: Patients enrolled in SEQUOIA-HCM with CPET data available at baseline and 24 weeks (w24) were included. Linear regression models were used to assess associations between changes in echo parameters and CPET metrics (peak oxygen uptake [pVO 2 ], minute ventilation [VE]/carbon dioxide output [VCO 2 ], composite z score, and anerobic threshold [AT]) from baseline to w24, adjusting for baseline values and clinical covariates. The composite z score was defined as the mean of standardized changes in pVO 2 and inverse VE/VCO 2 slope, with equal weighting for each component, and higher scores indicating favorable exercise performance. Cubic spline regression was used to model the relationship between changes in echo parameters and changes in CPET metrics. Results: A total of 282 patients (age 59±13years, 59% male, baseline pVO 2 18.5±4.5 mL/kg/min) were included. After adjustment, per each 5 mL/m 2 decrease in left atrial volume index (LAVi), there was a 0.3 mL/kg/min increase in pVO 2 (p=0.02), a 0.5 unit decrease in VE/VCO 2 slope (p=0.005), a 0.07 unit increase in the composite z score (p=0.001), and a 9.5 mL/min increase in AT (p=0.05) ( Table 1 ). Improvement in measures of diastolic function (lateral e’ and E/e’) demonstrated highly significant association with improvements in both pVO 2 and the composite z score (p<0.001 for both), and modest correlation with improved AT. Decreases in inferolateral wall thickness were associated with improvements in all CPET measures except AT. Cubic spline curves illustrate the relationships between changes in LAVi, lateral E/e’, and pVO 2 ( Fig 1 ). Conclusions: Aficamten treatment resulted in the improvement of measures of diastolic function, including E/e’, along with evidence of LA remodeling, both of which were associated with enhanced exercise capacity. These findings highlight diastolic dysfunction as a key pathophysiologic feature in oHCM and identify modifiable metrics that may aid in monitoring therapeutic response.

Article Details

Journal Circulation
Volume / Issue Vol. 152, Issue Suppl_3
Published November 04, 2025
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (17)

H

Henri Lu

Lausanne University Hospital, Lausanne, Switzerland

N

Nicole Bart

ST VINCENTS HOSPITAL, Sydney, New South Wales, Australia

B

Brian Claggett

Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston

T

Theodore Abraham

Department of Cardiology, University of, California, San Francisco, San Francisco

C

Caroline Coats

University og Glasgow, Glasgow, United Kingdom

M

Matthew Lee

G

Gregory Lewis

Massachusetts General Hospital, Boston, Massachusetts, United States

M

Martin maron

Lahey Hospital, Burlington, Massachusetts, United States

A

Ahmad Masri

Oregon Health and Science University, Portland

I

Iacopo Olivotto

Department of Cardiology, Meyer Children’s Hospital, IRCCS, Florence, Italy

D

Daniel Jacoby

Cytokinetics Inc., South San Francisco, California, United States

S

Stephen Heitner

Cytokinetics Inc., South San Francisco, California, United States

S

Stuart Kupfer

Cytokinetics, South San Francisco, CA

F

Fady Malik

Cytokinetics Inc., South San Francisco, California, United States

A

Amy Wohltman

Cytokinetics, South San Francisco, CA

S

Scott Solomon

Brigham and Women's Hospital, Boston, Massachusetts, United States

S

Sheila Hegde

The University of Texas Southwestern Medical Center, Dallas, Texas, United States